Jefferies Group LLC started coverage on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a research report released on Monday, July 10th, Marketbeat reports. The brokerage issued a buy rating and a $85.00 price objective on the biotechnology company’s stock. Jefferies Group also issued estimates for Spark Therapeutics’ Q2 2017 earnings at ($1.74) EPS, Q3 2017 earnings at ($1.78) EPS, Q4 2017 earnings at ($1.18) EPS, FY2017 earnings at ($6.39) EPS and FY2018 earnings at ($5.90) EPS.
Several other equities research analysts also recently weighed in on ONCE. UBS AG started coverage on Spark Therapeutics in a report on Wednesday, March 29th. They issued a buy rating and a $70.00 price target on the stock. BMO Capital Markets reiterated an outperform rating and issued a $69.00 price target on shares of Spark Therapeutics in a report on Friday, April 7th. Stifel Nicolaus restated a buy rating and set a $76.00 price objective on shares of Spark Therapeutics in a report on Monday, April 10th. Cantor Fitzgerald set a $94.00 price objective on Spark Therapeutics and gave the stock a buy rating in a report on Tuesday, May 9th. Finally, Wedbush restated an underperform rating and set a $28.00 price objective on shares of Spark Therapeutics in a report on Wednesday, May 10th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $82.27.
Spark Therapeutics (ONCE) traded up 0.19% during trading on Monday, hitting $78.78. 823,813 shares of the company traded hands. The stock has a 50-day moving average price of $64.99 and a 200-day moving average price of $59.11. Spark Therapeutics has a 12-month low of $35.07 and a 12-month high of $80.89. The firm’s market capitalization is $2.44 billion.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter last year, the company earned ($1.04) earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Equities analysts expect that Spark Therapeutics will post ($7.35) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was first reported by BBNS and is the property of of BBNS. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://baseballnewssource.com/markets/jefferies-group-llc-begins-coverage-on-spark-therapeutics-inc-once-updated-updated-updated/1197546.html.
In other Spark Therapeutics news, Director Anand Mehra sold 6,302 shares of Spark Therapeutics stock in a transaction dated Wednesday, June 21st. The stock was sold at an average price of $65.00, for a total transaction of $409,630.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 28,650 shares of Spark Therapeutics stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $80.01, for a total value of $2,292,286.50. Following the transaction, the chief executive officer now owns 258,650 shares of the company’s stock, valued at approximately $20,694,586.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 314,310 shares of company stock valued at $21,866,838. 7.30% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in ONCE. Russell Investments Group Ltd. bought a new position in Spark Therapeutics during the fourth quarter worth $883,000. State Board of Administration of Florida Retirement System raised its position in shares of Spark Therapeutics by 4.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 8,204 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 320 shares in the last quarter. State Street Corp raised its position in shares of Spark Therapeutics by 12.4% in the fourth quarter. State Street Corp now owns 902,606 shares of the biotechnology company’s stock valued at $45,044,000 after buying an additional 99,792 shares in the last quarter. Guggenheim Capital LLC acquired a new position in shares of Spark Therapeutics during the fourth quarter valued at $2,413,000. Finally, Norges Bank acquired a new position in shares of Spark Therapeutics during the fourth quarter valued at $8,232,000. Institutional investors and hedge funds own 88.95% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with our FREE daily email newsletter.